欧州医薬品庁(EMA)が、ニボルマブについて、悪性黒色腫の術後療法としての単剤使用の適応承認を支持

EMA Recommends Extension of Indications for Nivolumab


On 28 June 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product nivolumab (Opdivo).

 

 

 

コメント

Leave a comment

Your email address will not be published.


*